Acute dopamine D2 receptor signalling
Cell-based study · HEK-293 cells stably expressing human dopamine D2 receptors (HEK-D2). [1]
Paliperidone increased forskolin-stimulated cAMP accumulation and reduced basal ERK activity, consistent with inverse agonism in these acute assays. Responses exceeded those of risperidone in the reported comparisons.
| Endpoint | Reported result | Reference |
|---|---|---|
| Forskolin-stimulated cAMP accumulation (six independent experiments; bars mean ± SEM) | Reported direction and statistical comparison Increased versus vehicle; paliperidone greater than risperidone, P < 0.05. | [1] |
| Basal ERK activity (five independent experiments; bars mean ± SEM) | Approximate reduction reported in text Approximately 35%; paliperidone greater inverse agonist efficacy than risperidone, P < 0.05. | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- Paliperidone 200 nM; risperidone 300 nM and butaclamol 1 μM as separate comparators.
- Exposure duration
- cAMP: 15 min ligand pretreatment followed by an additional 15 min with forskolin; ERK: 5 min ligand treatment.
- Method
- cAMP measured by RIA with forskolin 1 μM; pERK measured using the SureFire assay.
- Co-treatment
- Forskolin 1 μM stimulates adenylyl cyclase in the cAMP assay; comparator ligands were tested separately.
- Reported limits
- Vehicle composition is not specified in the acquired Methods. Exact cAMP effect magnitude is not adopted because text and plotted normalization differ.
Methods and source locations
Compound reported in the paper: Paliperidone; Compound label in the paper: Paliperidone (9-hydroxyrisperidone)
Results concern the named research compound in receptor-expressing cells; no salt conversion, ester equivalence or lot validation is inferred.
Figure 6A–B; Results/Dopamine D2 receptor signalling; Methods/Cell culture, cAMP accumulation and ERK activity
Forskolin-stimulated cAMP accumulation (six independent experiments; bars mean ± SEM): RIA; vehicle and separate butaclamol/risperidone comparators; quinpirole positive control inhibited cAMP as reported in caption. — Figure 6A image/caption; Methods/cAMP accumulation; Results/Dopamine D2 receptor signalling
Basal ERK activity (five independent experiments; bars mean ± SEM): SureFire pERK assay; acute 5 min exposure; Figure 6B comparison marker checked visually. No exact value or SEM estimated from bars. — Figure 6B image/caption; Results/Dopamine D2 receptor signalling; Methods/ERK activity